These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15840411)

  • 21. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection.
    Rikitake Y; Kim HH; Huang Z; Seto M; Yano K; Asano T; Moskowitz MA; Liao JK
    Stroke; 2005 Oct; 36(10):2251-7. PubMed ID: 16141422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Rho-kinase inactivation on eosinophilia and hyper-reactivity in murine airways by allergen challenges.
    Taki F; Kume H; Kobayashi T; Ohta H; Aratake H; Shimokata K
    Clin Exp Allergy; 2007 Apr; 37(4):599-607. PubMed ID: 17430358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fasudil ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats: a possible role of Rho kinase.
    Hofni A; Shehata Messiha BA; Mangoura SA
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Aug; 390(8):801-811. PubMed ID: 28493050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fasudil, a Rho-kinase inhibitor, inhibits leukocyte adhesion in inflamed large blood vessels in vivo.
    Slotta JE; Braun OO; Menger MD; Thorlacius H
    Inflamm Res; 2006 Sep; 55(9):364-7. PubMed ID: 17122957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats.
    Okamura N; Saito M; Mori A; Sakamoto K; Kametaka S; Nakahara T; Ishii K
    J Ocul Pharmacol Ther; 2007 Jun; 23(3):207-12. PubMed ID: 17593003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice.
    Mallat Z; Gojova A; Sauzeau V; Brun V; Silvestre JS; Esposito B; Merval R; Groux H; Loirand G; Tedgui A
    Circ Res; 2003 Oct; 93(9):884-8. PubMed ID: 14525807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats.
    Jiang BH; Tawara S; Abe K; Takaki A; Fukumoto Y; Shimokawa H
    J Cardiovasc Pharmacol; 2007 Feb; 49(2):85-9. PubMed ID: 17312448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats.
    Kanda T; Wakino S; Hayashi K; Homma K; Ozawa Y; Saruta T
    Kidney Int; 2003 Dec; 64(6):2009-19. PubMed ID: 14633123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome.
    Schinzari F; Tesauro M; Rovella V; Di Daniele N; Gentileschi P; Mores N; Campia U; Cardillo C
    Am J Physiol Endocrinol Metab; 2012 Sep; 303(6):E806-11. PubMed ID: 22829585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.
    Ying H; Biroc SL; Li WW; Alicke B; Xuan JA; Pagila R; Ohashi Y; Okada T; Kamata Y; Dinter H
    Mol Cancer Ther; 2006 Sep; 5(9):2158-64. PubMed ID: 16985048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats.
    Li F; Xia W; Li A; Zhao C; Sun R
    Pharmacol Res; 2007 Jan; 55(1):64-71. PubMed ID: 17127075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice.
    Wu DJ; Xu JZ; Wu YJ; Jean-Charles L; Xiao B; Gao PJ; Zhu DL
    Atherosclerosis; 2009 Nov; 207(1):68-73. PubMed ID: 19473657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term inhibition of Rho kinase suppresses intimal thickening in autologous vein grafts in rabbits.
    Furuyama T; Komori K; Shimokawa H; Matsumoto Y; Uwatoku T; Hirano K; Maehara Y
    J Vasc Surg; 2006 Jun; 43(6):1249-56. PubMed ID: 16765249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fasudil attenuates lipopolysaccharide-induced acute lung injury in mice through the Rho/Rho kinase pathway.
    Li Y; Wu Y; Wang Z; Zhang XH; Wu WK
    Med Sci Monit; 2010 Apr; 16(4):BR112-118. PubMed ID: 20357711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition.
    Schlüter T; Steinbach AC; Steffen A; Rettig R; Grisk O
    Cardiovasc Res; 2008 Nov; 80(2):271-9. PubMed ID: 18596059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.
    Masumoto A; Mohri M; Shimokawa H; Urakami L; Usui M; Takeshita A
    Circulation; 2002 Apr; 105(13):1545-7. PubMed ID: 11927519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure.
    Kishi T; Hirooka Y; Masumoto A; Ito K; Kimura Y; Inokuchi K; Tagawa T; Shimokawa H; Takeshita A; Sunagawa K
    Circulation; 2005 May; 111(21):2741-7. PubMed ID: 15927989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina.
    Utsunomiya T; Satoh S; Ikegaki I; Toshima Y; Asano T; Shimokawa H
    Br J Pharmacol; 2001 Dec; 134(8):1724-30. PubMed ID: 11739249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of high-fat diet and voluntary running on body weight and endothelial function in LDL receptor knockout mice.
    Langbein H; Hofmann A; Brunssen C; Goettsch W; Morawietz H
    Atheroscler Suppl; 2015 May; 18():59-66. PubMed ID: 25936306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Rho-kinase stimulates nitric oxide-independent vasorelaxation.
    Löhn M; Steioff K; Bleich M; Busch AE; Ivashchenko Y
    Eur J Pharmacol; 2005 Jan; 507(1-3):179-86. PubMed ID: 15659308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.